Vis enkel innførsel

dc.contributor.authorHelland, Thomasen_US
dc.contributor.authorHenne, Ninaen_US
dc.contributor.authorBifulco, Ersiliaen_US
dc.contributor.authorNaume, Bjørnen_US
dc.contributor.authorBorgen, Elinen_US
dc.contributor.authorKristensen, Vessela N.en_US
dc.contributor.authorKvaløy, Jan Terjeen_US
dc.contributor.authorLash, Timothy Len_US
dc.contributor.authorGrenaker, Grethe Ireneen_US
dc.contributor.authorvan Schaik, RHNen_US
dc.contributor.authorJanssen, Emielen_US
dc.contributor.authorHustad, Simon Steinaren_US
dc.contributor.authorLien, Ernst Asbjørnen_US
dc.contributor.authorMellgren, Gunnaren_US
dc.contributor.authorSøiland, Håvarden_US
dc.date.accessioned2018-02-13T14:10:29Z
dc.date.available2018-02-13T14:10:29Z
dc.date.issued2017-11-28
dc.PublishedHelland T, Henne N, Bifulco E, Naume B, Borgen E, Kristensen VN, Kvaløy JT, Lash TL, Grenaker GI, van Schaik R, Janssen EAM, Hustad S, Lien EA, Mellgren G, Søiland H. Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients. Breast Cancer Research. 2017;19:125eng
dc.identifier.issn1465-542X
dc.identifier.urihttps://hdl.handle.net/1956/17391
dc.description.abstractBackground: Controversies exist as to whether the genetic polymorphisms of the enzymes responsible for the metabolism of tamoxifen can predict breast cancer outcome in patients using adjuvant tamoxifen. Direct measurement of concentrations of active tamoxifen metabolites in serum may be a more biological plausible and robust approach. We have investigated the association between CYP2D6 genotypes, serum concentrations of active tamoxifen metabolites, and long-term outcome in tamoxifen treated breast cancer patients. Methods: From an original observational study comprising 817 breast cancer patients, 99 women with operable breast cancer were retrospectively included in the present study. This cohort of patients were adjuvantly treated with tamoxifen, had provided serum samples suitable for measuring tamoxifen metabolites, and were relapse-free at 3 years after the primary treatment commenced. The median follow-up time from this entry point to breast cancer death was 13.9 years. Patients were CYP2D6 genotyped and grouped into four CYP2D6 phenotype groups (Ultra rapid, extensive, intermediate, and poor metabolizers). Tamoxifen and nine metabolites were quantified in serum (n = 86) and compared with CYP2D6 phenotype groups and outcome. Results: Breast cancer patients with low concentrations of Z-4-hydroxy-tamoxifen (Z-4OHtam; ≤ 3.26 nM) had a breast cancer-specific survival (BCSS) of 60% compared to 84% in patients with Z-4OHtam concentrations > 3.26 nM (p = 0.020, log-rank hazard ratio (HR) = 3.56, 95% confidence interval (CI) = 1.14–11.07). For patients with Z-4-hydroxy-N-desmethyltamoxifen (Z-endoxifen) levels ≤ 9.00 nM BCSS was 57% compared to 84% for patients with concentrations > 9.00 nM (p = 0.029, HR = 3.73, 95% CI = 1.05–13.22). Low concentrations of Z-4OHtam and Z-endoxifen were associated with poorer survival also after adjusting for clinically relevant variables (HR = 4.27, 95% CI = 1.35–13.58, and HR = 3.70, 95% CI = 1.03–13.25, respectively). Overall survival analysis showed similar survival differences for both active metabolites. The Antiestrogen Activity Score showed comparable effects, but did not improve the prognostic information. Conclusions: Patients with Z-4OHtam and Z-endoxifen concentrations lower than 3.26 nM or 9.00 nM, respectively, showed an adverse outcome. Our results suggest that direct measurement of active tamoxifen metabolite concentrations could be of clinical value. Validation in larger study cohorts is warranted.en_US
dc.language.isoengeng
dc.publisherBioMed Centraleng
dc.relation.ispartof<a href="http://hdl.handle.net/1956/20475" target="blank"> Tamoxifen in the treatment of luminal breast cancer. Implications of active metabolites on gene expression, side effects and clinical outcome</a>
dc.relation.urihttps://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-017-0916-4
dc.rightsAttribution CC BYeng
dc.rights.urihttp://creativecommons.org/licenses/by/4.0eng
dc.subjectTamoxifeneng
dc.subjectAdjuvanteng
dc.subjectMetabolismeng
dc.subjectSurvivaleng
dc.subjectCYP2D6eng
dc.subjectEndoxifeneng
dc.subject4OHtameng
dc.subjectBreast cancereng
dc.subjectPrognosiseng
dc.titleSerum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patientsen_US
dc.typePeer reviewed
dc.typeJournal article
dc.date.updated2018-01-30T15:00:47Z
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2017 The Author(s)
dc.subject.hrcsKreft: Evaluering av behandlinger og terapeutiske intervensjoner
dc.subject.hrcsCancer : Evaluation of Treatments and Therapeutic Interventions
dc.identifier.doihttps://doi.org/10.1186/s13058-017-0916-4
dc.identifier.cristin1540879
dc.source.journalBreast Cancer Research
dc.subject.nsiVDP::Medisinske fag: 700
dc.subject.nsiVDP::Midical sciences: 700


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution CC BY
Med mindre annet er angitt, så er denne innførselen lisensiert som Attribution CC BY